Spinal muscular atrophy with lower extremity predominance
Spinal muscular atrophy with lower extremity predominance (SMA-LED or SMALED) is a type of spinal muscular atrophy (SMA) that primarily affects the lower limbs. It is generally considered to be a very rare disease, although its true prevalence is unknown.
The disease may sometimes be referred to by other names, such as lower extremity dominant SMA, spinal muscular atrophy-lower extremity dominant, or lower extremity-predominant autosomal dominant proximal spinal muscular atrophy with contractures.
What is SMA-LED?
SMA-LED is a rare form of SMA, a group of genetic disorders characterized by degeneration of the nerve cells that control muscle movements (motor neurons), causing muscle weakness and wasting.
It is caused by mutations in one of two genes — DYNC1H1 or BICD2 — and mainly affects the lower limbs. It may emerge any time between infancy and adulthood, but most people start experiencing symptoms in infancy or early childhood. The disease usually progresses very slowly or stays stable over time.
What causes SMA-LED?
SMA-LED is classified into two types based on the underlying genetic cause: SMA-LED type 1 is caused by mutations in DYNC1H1, while SMA-LED type 2 is caused by mutations in BICD2.
Both genes contain instructions that cells use to manufacture proteins involved in the dynein complex, a system that moves materials through cells. The transport of signaling molecules via this system enables nerve cells to communicate with each other and with muscles. Disease-causing mutations disrupt the transport process and impair the development and maintenance of motor neurons, in turn leading to muscle weakness and wasting.
Researchers don’t know why SMA-LED primarily affects the lower limbs, but some propose that it is because motor neurons in this area must transport materials over longer distances and are therefore more affected by dynein complex dysfunction. BICD2 mutations may also contribute to the breakdown of the Golgi apparatus, a cellular component that modifies proteins and prepares them for transport.
SMA-LED is an autosomal dominant SMA type, meaning that someone only needs to inherit a disease-causing mutation from one parent to develop the condition. Sometimes the disease arises in a person without a family history of the disease.
Mutations in DYNC1H1 can also cause other neurodevelopmental or neuromuscular diseases with symptoms overlapping with those of DYNC1H1-SMA (SMA-LED type 1). BICD2-SMA (SMA-LED type 2) is sometimes further classified into SMA-LED2A, a milder form of the disease, and SMA-LED2B, a more severe subtype.
What are the symptoms of SMA-LED?
The hallmark symptom of SMA-LED is lower limb weakness and wasting for both disease types. Muscle weakness most often emerges in infancy or early childhood, but about a quarter of people don’t develop problems until adulthood.
In particular, SMA-LED causes proximal leg weakness, or weakness in the part of the leg closest to the core of the body, especially the thigh muscles. This can cause walking and mobility problems such as:
- Delayed motor milestones in children
- Wobbling or unsteady walk
- Walking on the balls of the feet
- Difficulty rising from a seated position or climbing stairs
The disease may also cause deformities in the joints of the lower limbs, including in the knees, hips, feet, or ankles, which further contribute to mobility issues.
Other less common SMA-LED symptoms include:
- Altered brain development and neurological symptoms, such as cognitive impairment, attention deficit hyperactivity disorder (ADHD), intellectual disability, or seizures
- Upper limb or trunk weakness
- Joint rigidity in the shoulders, elbows, or hands
- Respiratory problems, particularly in SMA-LED2B
How is SMA-LED diagnosed?
Because the condition is very rare, it can be difficult to reach an SMA-LED diagnosis. The diagnostic process may involve the following:
- Review of symptoms and family history: Identifies patterns consistent with SMA-LED or a relevant family history of disease
- Muscle MRI: Imaging scan to visualize problems with muscles
- Genetic testing: Identify DYNC1H1 or BICD2 mutations
- eEectromyography (EMG): Identifies problems with muscles and the nerves that control them, which can help distinguish SMA-LED from other neuromuscular disorders
- Muscle biopsy: A small sample of muscle tissue that can be examined under a microscope for cellular changes consistent with SMA-LED
Throughout the diagnostic process and afterward, conversations with a genetic counselor can help patients and families understand their test results and make family planning decisions.
How is SMA-LED treated?
Currently, there are no available SMA-LED treatments that can slow disease progression. However, supportive care can help ease symptoms and improve quality of life. Depending on an individual’s needs, this may include:
- Specialized equipment and adaptive aids to improve mobility
- Physical therapy
- Occupational therapy
Because mobility-related symptoms are common, adaptive strollers and wheelchairs, walkers, and other assistive devices can be particularly useful for people living with SMA-LED.
What is the outlook for people with SMA-LED?
The course of SMA-LED can vary, but for many, the disease progresses very slowly or remains stable over the long term. Most people will retain some ability to walk, although some people may need supportive devices or equipment to do so.
SMA-LED typically does not cause the severe breathing muscle weakness that can affect life expectancy in other forms of SMA. However, survival data for this very rare form of the disease are lacking.
A minority of people with severe disease may experience more substantial disease progression or complications.
Questions to ask your healthcare team
Given the rarity of SMA-LED, healthcare providers are essential sources of personalized, up-to-date information. People with SMA-LED and their families may want to ask about:
- Options for treating their specific symptoms
- Next steps for monitoring disease progression
- Symptoms that may require urgent medical attention
- Genetic counseling and implications for family planning
- Referrals for physical or occupational therapy
Mental health challenges are common after an SMA diagnosis. Counseling, support groups, and other mental healthcare resources may help some patients and families.
SMA News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
